

FBR Healthcare Series:

New Prescriptions: Innovation in the Treatment of Diseases and Infections



Wednesday, April 20, 2016 . JW Marriott Essex House . New York



Agenda*

8:00 a.m. Breakfast and Registration

8:30 a.m. The Human Microbiome and Applications in Novel Therapeutics

Pierre Belichard, Ph.D., Chief Executive Officer, **Enterome Bioscience (private)**

Reza Fathi, Ph.D., Senior Vice President of R&D, **RedHill Biopharma (RDHL)**

Jeff Riley, Chief Executive Officer, **Synthetic Biologics (SYN)**

Moderated by Vernon Bernardino, Senior Vice President, FBR

9:30 a.m. BARDA Funding Opportunities for Biotech Companies

Garrett Nichols, M.D., M.S., Chief Medical Officer, **Chimerix (CMRX)**

Kelly Childress Lange, Partner, **East End Group**

Jim Talton, Ph.D., Chief Executive Officer, Chief Scientific Officer, **Nanotherapeutics (private)**

Stan Erck, Chief Executive Officer, **Novavax (NVAX)**

Moderated by Ed White, Senior Vice President, FBR

10:30 a.m. Notable Emerging Anti-Viral Agents

Laura Sepp-Lorenzino, Ph.D., VP, Entrepreneur-in-Residence, **Alnylam Pharmaceuticals (ALNY)**

Joseph M. Patti, Ph.D., Chief Executive Officer and President, **Aviragen Therapeutics, Inc. (AVIR)**

Garrett Nichols, M.D., M.S., Chief Medical Officer, **Chimerix (CMRX)**

Paul Grint, M.D., Chief Executive Officer, **Regulus Therapeutics (RGLS)**

Moderated by Christopher James, M.D., Senior Vice President, FBR

11:30 a.m. Showcase of Novel Technologies in Fighting Infections

Richard J. Benjamin, Ph.D., Chief Medical Officer, **Cerus Corporation (CERS)**

Randy Milby, Chief Executive Officer, **CorMedix (CRMD)**

Zachary Zimmerman, Ph.D., Chief Executive Officer, **Forge Therapeutics (private)**

Ron Spair, Chief Financial Officer, Chief Operating Officer, **OraSure Technologies (OSUR)**

Guy Macdonald, B.Sc., Chief Executive Officer, **Tetraphase Pharmaceuticals (TTPH)**

Moderated by Thomas Yip, Assistant Vice President, FBR

12:30 p.m. Keynote Lunch

Robin Robinson, Ph.D., retired Director, BARDA

Moderated by Chris Meekins, Vice President, FBR

1:30 p.m. Adjourn for one-on-one meetings

*The schedule is subject to change without notice.

This conference is sponsored by FBR Capital Markets & Co.

See www.fbr.com/disclosures for disclosures about FBR Research.